Detalhe da pesquisa
1.
SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Ophthalmology
; 130(10): 1066-1072, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37220815
2.
SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
Graefes Arch Clin Exp Ophthalmol
; 260(5): 1491-1500, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-34842984
3.
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
Graefes Arch Clin Exp Ophthalmol
; 259(7): 1839-1851, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-33415354
4.
Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.
Genet Med
; 21(5): 1189-1198, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30270358
6.
Molecular genetic findings and clinical correlations in 100 patients with Joubert syndrome and related disorders prospectively evaluated at a single center.
Genet Med
; 19(8): 875-882, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28125082
7.
SCORE2 Report 2: Study Design and Baseline Characteristics.
Ophthalmology
; 124(2): 245-256, 2017 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27863843
8.
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
JAMA
; 317(20): 2072-2087, 2017 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-28492910
9.
Month 60 Imaging Findings and Relationship to Treatment Outcomes Following Anti-VEGF Therapy for Macular Edema Due to Central or Hemi-Retinal Vein Occlusion.
Am J Ophthalmol
; 260: 147-159, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38061584
10.
Association of Retinal Thickness at Month 1 Post-Treatment with Later Thickness and Visual Acuity in Central Vein Occlusion.
Am J Ophthalmol
; 2024 May 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38705553
11.
SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.
Am J Ophthalmol
; 248: 157-163, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36584835
12.
OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.
Am J Ophthalmol
; 256: 55-62, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37544495
13.
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
JAMA Ophthalmol
; 141(6): 554-561, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37166820
14.
High Variation in Inner Retinal Reflectivity Predicts Poor Visual Outcome in Patients With Central Retinal Vein Occlusion: SCORE2 Report 21.
Transl Vis Sci Technol
; 12(6): 21, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37367722
15.
Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion.
Am J Ophthalmol
; 240: 330-341, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35461831
16.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
JAMA Ophthalmol
; 140(5): 458-464, 2022 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35323843
17.
Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.
Ophthalmology
; 118(2): 345-52, 2011 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-20926135
18.
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
Ophthalmology
; 118(7): 1364-72, 2011 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-21440942
19.
Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.
Am J Drug Alcohol Abuse
; 37(5): 350-7, 2011 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-21854277
20.
Design of NIDA CTN Protocol 0047: screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED).
Am J Drug Alcohol Abuse
; 37(5): 417-25, 2011 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-21854285